1451P - Breast cancer specific survival (BCSS) in young woman

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancer in Adolescents
Cancer in Young Adults
Bioethics, Legal, and Economic Issues
Breast Cancer
Presenter Steven Shak
Citation Annals of Oncology (2017) 28 (suppl_5): v511-v520. 10.1093/annonc/mdx385
Authors S. Shak1, M. Roberts2, D. Miller1, A. Kurian3, V. Petkov2
  • 1Translational Sciences, Genomic Health Inc, 94063 - Redwood City/US
  • 2Cancer Control And Population Sciences, National Cancer Institute, Bethesda/US
  • 3Departments Of Medicine (oncology) And Of Health Research & Policy, Stanford University School of Medicine, 94305 - Stanford/US



BC at a young age is generally associated with poor prognosis, more aggressive treatment, long-term toxicities, and unique psychosocial concerns. Little data is available on outcomes defined by molecular profiles. We characterized BCSS in female patients (pts)


RS results were provided electronically to SEER (US population based cancer registries) per their linkage methods (Petkov et al, npj Breast Cancer, 2016). Eligible pts were diagnosed (Jan 2004 - Dec 2012) with N0 HR+ BC, and had no prior malignancy or multiple tumors. BCSS was analyzed for female pts


1,761 of 7,186 pts


This large population-based study of N0 HR+ HER2- BC indicates not all young women have aggressive tumor biology and poor prognosis. Nearly half (47%) of women

Clinical trial identification

Legal entity responsible for the study

National Cancer Institute


National Cancer Institute


S. Shak: Full-time employee of Genomic Health and a shareholder of Genomic Health. D. Miller: Employee of Genomic Health. All other authors have declared no conflicts of interest.